Compare Adaptive Biotechnologies Corp (ADPT) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ross Stores, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B), while Ross Stores, Inc. trades at $249.18 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 20× Adaptive Biotechnologies Corp's market cap, and Ross Stores, Inc. pays a 0.71% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ROST | |
|---|---|---|
Market Cap | $4.04B | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $255.23 |
52-Week Low | $12.30 | $144.67 |
Enterprise Value | $4.10B | $81.37B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Ross Stores (ROST) trades at $254.83, near its consensus price target of $259.00, with a slight 0.16% decline. The stock shows strong fundamentals, including a 9.74% net income margin and 38.98% ROE for 2025, with recent quarterly earnings consistently beating estimates. Technical indicators are bullish, supported by positive moving averages and recent store expansion news.
The outlook remains positive due to robust earnings growth and analyst buy ratings (63.83% consensus). Key risks include high valuation multiples (P/E of 35.17) and competitive pressures in discount retail. Upside potential exists if Q2 2026 earnings beat expectations, but macroeconomic headwinds could pressure consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
